SCHEMBL15919456

SCHEMBL15919456

CC(=O)NCc1cc(-c2ccc(-c3ccc(-c4cc(C(=O)NNCl)c5cnccc5n4)cc3)cc2)no1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.53
SMN1; SMN2 Q16637 4/20 0.48
CYP1A2 P05177 1/20 0.48
TSHR P16473 3/20 0.42
MAPK1 P28482 1/20 0.41
LMNA P02545 3/20 0.41
ALDH1A1 P00352 5/20 0.41
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
MAPT P10636 2/20 0.41
KDM4E B2RXH2 2/20 0.41
USP2 O75604 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HTT P42858 3/20 0.40
JAK2 O60674 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
NPC1 O15118 1/20 0.38
TP53 P04637 1/20 0.38
RAB9A P51151 1/20 0.38
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15904787 0.90 POLB (0.53) POLBSMN1; SMN2CYP1A2TSHRMAPK1
Hydrochloric Acid SCHEMBL17313789 0.89 POLB (0.52) POLBSMN1; SMN2CYP1A2TSHRMAPK1
SCHEMBL15919455 0.89 SMN1; SMN2 (0.56) POLBSMN1; SMN2CYP1A2TSHRMAPK1
SCHEMBL15919454 0.87 SMN1; SMN2 (0.57) POLBSMN1; SMN2CYP1A2TSHRMAPK1
SCHEMBL15919453 0.87 CYP1A2 (0.46) POLBSMN1; SMN2CYP1A2TSHRMAPK1
SCHEMBL17327503 0.84 MAPT (0.38) TSHRLMNAALDH1A1MEN1KMT2A
SCHEMBL15919473 0.82 DHODH (0.42) POLBTSHRLMNAALDH1A1MEN1
SCHEMBL15905018 0.81 ALDH1A1 (0.43) POLBSMN1; SMN2CYP1A2TSHRMAPK1
SCHEMBL15919272 0.81 PLA2G2A (0.46) POLBSMN1; SMN2CYP1A2TSHRMAPK1
SCHEMBL15919268 0.79 SMN1; SMN2 (0.45) POLBSMN1; SMN2CYP1A2TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 US disclosed
WO-2014117090-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2014-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO POLB 1777/4885SMN1; SMN2 1142/4885CYP1A2 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.